Assessing the potential for non-digestible carbohydrates toward mitigating adverse effects of antibiotics on microbiota composition and activity in an in vitro colon model of the weaning infant

FEMS Microbiol Ecol. 2025 Mar 18;101(4):fiaf028. doi: 10.1093/femsec/fiaf028.

Abstract

Environmental factors like diet and antibiotics modulate the gut microbiota in early life. During weaning, gut microbiota progressively diversifies through exposure to non-digestible carbohydrates (NDCs) from diet, while antibiotic perturbations might disrupt this process. Supplementing an infant's diet with prebiotic NDCs may mitigate the adverse effects of antibiotics on gut microbiota development. This study evaluated the influence of supplementation with 2-fucosyllactose (2'-FL), galacto-oligosaccharides (GOS), or isomalto/malto-polysaccharides containing 87% of α(1→6) linkages (IMMP-87), on the recovery of antibiotic-perturbed microbiota. The TIM-2 in vitro colon model inoculated with fecal microbiota of 9-month-old infants was used to simulate the colon of weaning infants exposed to the antibiotics amoxicillin/clavulanate or azithromycin. Both antibiotics induced changes in microbiota composition, with no signs of recovery in azithromycin-treated microbiota within 72 h. Moreover, antibiotic exposure affected microbiota activity, indicated by a low valerate production, and azithromycin treatment was associated with increased succinate production. The IMMP-87 supplementation promoted the compositional recovery of amoxicillin/clavulanate-perturbed microbiota, associated with the recovery of Ruminococcus, Ruminococcus gauvreauii group, and Holdemanella. NDC supplementation did not influence compositional recovery of azithromycin-treated microbiota. Irrespective of antibiotic exposure, supplementation with 2'-FL, GOS, or IMMP-87 enhanced microbiota activity by increasing short-chain fatty acids production (acetate, propionate, and butyrate).

Keywords: 2′-FL; GOS; IMMP; amoxicillin/clavulanate; azithromycin; gut bacteria.

MeSH terms

  • Amoxicillin-Potassium Clavulanate Combination / adverse effects
  • Amoxicillin-Potassium Clavulanate Combination / pharmacology
  • Anti-Bacterial Agents* / adverse effects
  • Anti-Bacterial Agents* / pharmacology
  • Azithromycin / adverse effects
  • Azithromycin / pharmacology
  • Bacteria / classification
  • Bacteria / drug effects
  • Bacteria / genetics
  • Colon* / drug effects
  • Colon* / microbiology
  • Dietary Carbohydrates*
  • Fatty Acids, Volatile / metabolism
  • Feces / microbiology
  • Gastrointestinal Microbiome* / drug effects
  • Humans
  • Infant
  • Oligosaccharides
  • Prebiotics
  • Trisaccharides
  • Weaning

Substances

  • Anti-Bacterial Agents
  • Prebiotics
  • Azithromycin
  • Amoxicillin-Potassium Clavulanate Combination
  • Oligosaccharides
  • Trisaccharides
  • 2'-fucosyllactose
  • Dietary Carbohydrates
  • Fatty Acids, Volatile